January 25, 2017 09:17 AM EST

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

John Carroll

Editor & Founder

One of the reasons why Novartis isn’t being forced to bid into the stratosphere for late-stage drugs is that its industry-topping R&D budget — $9 billion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Fight­ing a gener­ic on­slaught, No­var­tis adds CAR-T to its grow­ing list of late-stage block­busters

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life